NASDAQ:PEPG PepGen (PEPG) Stock Price, News & Analysis → Bombshell 2024 election documentary (From Porter & Company) (Ad) Free PEPG Stock Alerts $14.70 +0.61 (+4.33%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$14.00▼$14.9050-Day Range$6.73▼$17.3052-Week Range$3.72▼$17.51Volume30,717 shsAverage Volume123,464 shsMarket Capitalization$475.60 millionP/E RatioN/ADividend YieldN/APrice Target$24.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get PepGen alerts: Email Address PepGen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside67.8% Upside$24.67 Price TargetShort InterestHealthy1.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingAcquiring Shares$27.21 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.88) to ($2.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.69 out of 5 starsMedical Sector487th out of 939 stocksPharmaceutical Preparations Industry235th out of 444 stocks 3.5 Analyst's Opinion Consensus RatingPepGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.67, PepGen has a forecasted upside of 67.8% from its current price of $14.70.Amount of Analyst CoveragePepGen has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.31% of the float of PepGen has been sold short.Short Interest Ratio / Days to CoverPepGen has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PepGen has recently increased by 21.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPepGen does not currently pay a dividend.Dividend GrowthPepGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PEPG. Previous Next 2.5 News and Social Media Coverage News SentimentPepGen has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for PepGen this week, compared to 1 article on an average week.Search Interest7 people have searched for PEPG on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added PepGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PepGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $27,212,790.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.97% of the stock of PepGen is held by insiders.Percentage Held by Institutions58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PepGen are expected to grow in the coming year, from ($2.88) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PepGen is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PepGen is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPepGen has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyBombshell 2024 election documentary 2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.All the facts are here. About PepGen Stock (NASDAQ:PEPG)PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Read More PEPG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PEPG Stock News HeadlinesMarch 13, 2024 | marketwatch.comPepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease DesignationsMarch 13, 2024 | globenewswire.comPepGen to Participate in Upcoming Investor ConferencesMarch 29, 2024 | Porter & Company (Ad)Bombshell 2024 election documentary 2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.March 13, 2024 | markets.businessinsider.comPepGen Secures FDA's Orphan Drug, Rare Pediatric Disease Designations For PGN-EDO51March 13, 2024 | globenewswire.comPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyMarch 12, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on PepGen Inc. (PEPG)March 9, 2024 | seekingalpha.comPepGen, Inc. (PEPG) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | investorplace.comPEPG Stock Earnings: PepGen Beats EPS for Q4 2023March 29, 2024 | Porter & Company (Ad)Bombshell 2024 election documentary 2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.March 6, 2024 | investing.comPepGen's DMD therapy advances to phase 2 trial in the UKMarch 6, 2024 | globenewswire.comPepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsMarch 4, 2024 | globenewswire.comPepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyFebruary 21, 2024 | msn.comFDA grants fast track to PepGen’s DM1 treatmentFebruary 20, 2024 | markets.businessinsider.comPepGen Receives U.S. FDA Fast Track Designation For PGN-EDODM1 For The Treatment Of DM1February 20, 2024 | finance.yahoo.comPepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1February 20, 2024 | globenewswire.comPepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1February 18, 2024 | 247wallst.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 8, 2024 | msn.comPepGen Inc. Secures Funding to Advance Research ProgramsFebruary 8, 2024 | msn.comPepGen Inc. Announces Pricing for Its OfferingFebruary 7, 2024 | tmcnet.comPepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockFebruary 7, 2024 | marketwatch.comPepGen Stock Higher After Follow-on OfferingFebruary 6, 2024 | msn.comPepGen soars on Sarepta Therapeutics' Duchenne drug phase 2 dataFebruary 2, 2024 | markets.businessinsider.comTop 4 Health Care Stocks That May Crash This QuarterJanuary 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for PepGen Inc. on Strong Prospects in DMD Treatment and Promising EDO PlatformJanuary 30, 2024 | msn.comPepGen stock soars after rival Sarepta reports data for DMD drugJanuary 20, 2024 | seekingalpha.comPepGen: Long Road AheadJanuary 17, 2024 | finance.yahoo.comDay One Announces Two New Appointments to Board of DirectorsSee More Headlines Receive PEPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PepGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PEPG CUSIPN/A CIK1835597 Webwww.pepgen.com Phone781-797-0979FaxN/AEmployees64Year FoundedN/APrice Target and Rating Average Stock Price Target$24.67 High Stock Price Target$28.00 Low Stock Price Target$20.00 Potential Upside/Downside+67.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.56% Return on Assets-45.55% Debt Debt-to-Equity RatioN/A Current Ratio6.43 Quick Ratio6.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.55 per share Price / Book3.23Miscellaneous Outstanding Shares32,350,000Free Float31,070,000Market Cap$475.55 million OptionableNot Optionable Beta1.60 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. James G. McArthur Ph.D. (Age 62)President, CEO, Treasurer, Secretary & Director Comp: $834.98kMr. Noel P. Donnelly M.B.A. (Age 54)Chief Financial Officer Comp: $650.17kMr. Niels Svenstrup Ph.D. (Age 54)Senior Vice President of Chemistry, Manufacturing & Control Comp: $455.15kDr. Michael Gait Ph.D.Founder & Scientific Advisory Board MemberMs. Mary Beth DeLenaGeneral Counsel & SecretaryDr. Michelle L. Mellion M.D. (Age 48)Senior VP & Head of Clinical Development Ms. Emiko BryantChief of StaffMr. Kyle BreidenstineVP of Finance & ControllerMore ExecutivesKey CompetitorsTheravance BiopharmaNASDAQ:TBPHHarrow HealthNASDAQ:HROWAEON BiopharmaNASDAQ:AEONAvid BioservicesNASDAQ:CDMOShattuck LabsNASDAQ:STTKView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 3,386 shares on 3/11/2024Ownership: 2.126%Goldman Sachs Group Inc.Bought 14,156 shares on 3/1/2024Ownership: 0.059%Vanguard Group Inc.Bought 3,386 shares on 2/15/2024Ownership: 2.126%Bridgeway Capital Management LLCBought 42,900 shares on 2/15/2024Ownership: 0.417%Barclays PLCBought 12,096 shares on 2/15/2024Ownership: 0.058%View All Insider TransactionsView All Institutional Transactions PEPG Stock Analysis - Frequently Asked Questions Should I buy or sell PepGen stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PepGen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PEPG shares. View PEPG analyst ratings or view top-rated stocks. What is PepGen's stock price target for 2024? 2 equities research analysts have issued 12 month price objectives for PepGen's stock. Their PEPG share price targets range from $20.00 to $28.00. On average, they predict the company's share price to reach $24.67 in the next year. This suggests a possible upside of 67.8% from the stock's current price. View analysts price targets for PEPG or view top-rated stocks among Wall Street analysts. How have PEPG shares performed in 2024? PepGen's stock was trading at $6.80 at the start of the year. Since then, PEPG shares have increased by 116.2% and is now trading at $14.70. View the best growth stocks for 2024 here. Are investors shorting PepGen? PepGen saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 260,400 shares, an increase of 21.8% from the February 29th total of 213,800 shares. Based on an average daily trading volume, of 128,100 shares, the short-interest ratio is presently 2.0 days. Currently, 1.3% of the company's shares are short sold. View PepGen's Short Interest. When is PepGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PEPG earnings forecast. How were PepGen's earnings last quarter? PepGen Inc. (NASDAQ:PEPG) issued its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($1.01) by $0.19. What ETF holds PepGen's stock? Morningstar US Small Growth holds 3,223 shares of PEPG stock, representing 1.20% of its portfolio. When did PepGen IPO? PepGen (PEPG) raised $126 million in an initial public offering on Friday, May 6th 2022. The company issued 9,000,000 shares at $13.00-$15.00 per share. Who are PepGen's major shareholders? PepGen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.13%), Vanguard Group Inc. (2.13%), Bridgeway Capital Management LLC (0.42%), Goldman Sachs Group Inc. (0.06%), Goldman Sachs Group Inc. (0.06%) and Barclays PLC (0.06%). Insiders that own company stock include James G Mcarthur, Jaya Goyal and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of PepGen? Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PEPG) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss Ratings“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.